1. Home
  2. CRSP vs LBTYB Comparison

CRSP vs LBTYB Comparison

Compare CRSP & LBTYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.82

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Liberty Global Ltd. Class B

LBTYB

Liberty Global Ltd. Class B

N/A

Current Price

$14.72

Market Cap

4.5B

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
LBTYB
Founded
2013
2004
Country
Switzerland
Bermuda
Employees
N/A
6636
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.5B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
LBTYB
Price
$56.82
$14.72
Analyst Decision
Buy
Analyst Count
17
0
Target Price
$70.29
N/A
AVG Volume (30 Days)
1.4M
5.0K
Earning Date
05-05-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$743.50
$15.41
Revenue Next Year
$163.21
$1.80
P/E Ratio
N/A
N/A
Revenue Growth
9169.85
N/A
52 Week Low
$33.03
$9.20
52 Week High
$78.48
$29.01

Technical Indicators

Market Signals
Indicator
CRSP
LBTYB
Relative Strength Index (RSI) 65.66 60.28
Support Level $51.64 $11.60
Resistance Level $60.63 $14.58
Average True Range (ATR) 2.28 0.88
MACD 1.17 0.09
Stochastic Oscillator 94.14 87.19

Price Performance

Historical Comparison
CRSP
LBTYB

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About LBTYB Liberty Global Ltd. Class B

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: